Related Experiment Video
Updated: Apr 30, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer
L Alexis Hoeferlin1, Charles E Chalfant1, Margaret A Park1
1Hunter Holmes McGuire VAMC, Dept. of Research and Development, Richmond VA, 23224 ( ), Virginia Commonwealth University Reanimation Engineering Science Center (VCURES), Richmond, Virginia 23298 ( ), Massey Cancer Center, Virginia Commonwealth University, Richmond VA, 23298 ( and Virginia Commonwealth University, Dept. of Biochemistry and Molecular Biology, Richmond VA, 23298 ( ).
Abstract:
While the 5-year survival rate of breast cancer is at an all-time high of 90%, this disease remains the second most common cause of cancer-related death, surpassed only by lung cancer in the US. The reasons for this discrepancy stem from cancer subtypes which become resistant to current therapies. These subtypes: "Triple negative" and ErbB2-overexpressing, are discussed in this review.
Insights
Despite high survival rates for breast cancer, it remains a leading cause of cancer death due to therapy-resistant subtypes. This review focuses on triple-negative and ErbB2-overexpressing breast cancers.
Area of Science:
- Oncology
- Cancer Research
- Medical Science
Background:
- Breast cancer 5-year survival is 90%, yet it's the second leading cause of cancer death in the US.
- Therapy resistance in specific breast cancer subtypes contributes to mortality.
- Lung cancer is the leading cause of cancer death in the US.
Purpose of the Study:
- To review the challenges posed by therapy-resistant breast cancer subtypes.
- To discuss "Triple Negative" and ErbB2-overexpressing breast cancers.
Main Methods:
- Literature review of current research on breast cancer subtypes.
- Analysis of therapeutic resistance mechanisms.
- Discussion of clinical implications for targeted therapies.
Main Results:
- Identified "Triple Negative" and ErbB2-overexpressing breast cancers as key resistant subtypes.
- Highlighted the need for novel therapeutic strategies.
- Emphasized the discrepancy between overall survival rates and mortality from resistant forms.
Conclusions:
- "Triple Negative" and ErbB2-overexpressing breast cancers present significant therapeutic challenges.
- Further research is crucial for developing effective treatments for these aggressive subtypes.
- Addressing resistance is key to reducing breast cancer mortality.
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...